Investigators encourage further research on the use of NSAIDs in women with preeclampsia who develop postpartum hypertension.
Pregnancy-associated stroke risk is even higher in women with chronic hypertension, coagulopathies, and prothrombotic conditions.
Researchers examined the efficacy of aspirin in preventing preterm preeclampsia in women at risk.
Financial data for both mothers and children were examined through the first year of life.
Despite multiple measures and goals to reduce US maternal mortality rates, the latest data suggest the United States is far behind the rest of the world in maternal health care.
According to Journal of the American Heart Association, pregnant women with chronic hypertension using antihypertensive agents reduces the risk of hypertension without added risk to the fetus.
Women with preeclampsia should heed any neurological symptoms, which may be signs of a stroke.
Women at high risk for preeclampsia should take low-dose aspirin as a preventive therapy.
The relative risk for developing preeclampsia, determined using waist-to-hip ratio, was 3.317 vs 2.418 using BMI.
Endocrinology Advisor Articles
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Metformin and PCOS: Improving Menstrual Cycle and Hormone Profiles
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- T2D May Play a Protective Role Against Developing Aortic Diseases
- Risk Factors for Diabetes May Be Identified 20 Years Before Diagnosis
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Type 2 Diabetes Insulin Initiation: Predictors Identified
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Risk for Congenital Malformations With Antithyroid Drugs
- Occupational Therapy May Benefit Young Adults With Diabetes
- Weight Loss May Improve Pain in Patients With Obesity
- Prior Authorizations Are Creating a Challenge for Clinicians
- Effect of Biologic DMARDs on Spinal Fracture Risk in Ankylosing Spondylitis